NNZ-2591, A Novel IGF-1–Related Treatment for Neurodevelopmental Disorders, Demonstrates Efficacy for Children and Adolescents With Phelan-McDermid Syndrome
Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.
Start the conversation
Ask Neuren Pharmaceuticals a question about this update.
